Results 1 to 10 of about 719 (164)

Morphological and quantitative CT features of anterior mediastinal lesions in TAFRO syndrome and idiopathic multicentric Castleman disease [PDF]

Frontiers in Immunology
We investigated the diagnostic challenges of TAFRO syndrome and idiopathic multicentric Castleman disease (iMCD), focusing on the usefulness of anterior mediastinal lesions for distinguishing the disease subtypes.
Lamiaa Mohamed, Masataka Umeda, Masataka Umeda, Shin Tsutsui, Ryo Toya, Ayaka Umetsu, Mizuna Otsuka, Yushiro Endo, Toshimasa Shimizu, Shoichi Fukui, Remi Sumiyoshi, Atsushi Kawakami, Tomohiro Koga   +12 more
doaj   +5 more sources

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease [PDF]

Haematologica, 2022
Castleman disease is a polyclonal lymphoproliferative disorder characterized by unicentric or multicentric lymphadenopathy with characteristic histomorphological features, in addition to variable inflammatory symptomatology. The molecular mechanisms and
Pedro Horna, Rebecca L. King, Dragan Jevremovic, David C. Fajgenbaum, Angela Dispenzieri   +4 more
doaj   +3 more sources

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity [PDF]

Blood, 2021
Abstract Dysregulated inflammatory responses are characterized by inappropriate levels of inflammatory markers, speed of generation, degree, and major site of production, such as a vital organ. COVID-19 severity and mortality are strongly associated with interleukin (IL)-6 levels.
Rossi J, Chiang H, Lu Z, Levon K, van Rhee F, Kanhai K, Fajgenbaum D, Klein B.   +7 more
europepmc   +2 more sources

Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. [PDF]

J Clin Pathol
Aims and methods Idiopathic multicentric Castleman disease (iMCD) is currently considered to be classified into three clinical subtypes, including idiopathic plasmacytic lymphadenopathy (IPL), thrombocytopaenia, anasarca, fever, reticulin fibrosis/renal dysfunction, organomegaly (TAFRO) and not otherwise specified ...
Nishikori A, Nishimura MF, Fajgenbaum DC, Nishimura Y, Maehama K, Haratake T, Tabata T, Kawano M, Nakamura N, Momose S, Sumiyoshi R, Koga T, Yamamoto H, van Rhee F, Kawakami A, Sato Y.   +15 more
europepmc   +3 more sources

Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. [PDF]

Br J Haematol
SummaryIdiopathic multicentric Castleman disease (iMCD) is subclassified into iMCD‐thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly (TAFRO) and iMCD‐not otherwise specified (NOS) according to the Castleman Disease Collaborative Network (CDCN) consensus criteria.
Gao YH, Liu YT, Zhang MY, Li SY, Fajgenbaum DC, Zhang L, Li J.   +6 more
europepmc   +3 more sources

Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease [PDF]

Haematologica
Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder with heterogeneous presentations ranging from moderate constitutional symptoms to life-threatening multiorgan system involvement. iMCD patients present with vastly different
Mateo Sarmiento Bustamante, Sheila K. Pierson, Yue Ren, Adam Bagg, Joshua D. Brandstadter, Gordan Srkalovic, Natalie Mango, Daisy Alapat, Mary Jo Lechowicz, Hongzhe Li, Frits van Rhee, Megan S. Lim, David C. Fajgenbaum   +12 more
doaj   +3 more sources

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

Nature Communications, 2022
Idiopathic multicentric Castleman disease (iMCD) is a life-threatening inflammatory disease requiring immediate intervention, for which the recommended first-line therapy is the Interleukin-6 pathway inhibitor siltuximab.
Sheila K Pierson, Melanie D Mumau
exaly   +2 more sources

Atypical clinical presentation associated with Castleman disease: a case report and review of the literature [PDF]

Frontiers in Medicine
BackgroundCastleman disease (CD) is a group of rare and complicated diseases characterized by systemic inflammation, lymphadenopathy, and multiorgan involvement.
Weiwei Hu, Yuke Kong, Bianxiang Hu, Jun Ai, Peng Zhang   +4 more
doaj   +2 more sources

Long-term tolerance and efficacy of siltuximab (anti-IL-6) in a young adult with idiopathic multicentric Castleman disease during COVID-19 [PDF]

European Journal of Case Reports in Internal Medicine, 2023
Background: Castleman disease (CD) is a rare lymphoproliferative disorder with various subtypes, including the HHV-8-negative/idiopathic multicentric CD (iMCD).
Helbies Bedier, Stéphane Isnard, Chelsea Maedler-Kron, Jean-Pierre Routy   +3 more
doaj   +3 more sources

Are patients with HHV-8 associated Castleman disease successfully treated with rituximab at risk of subsequently developing HHV-8 negative (idiopathic) Castleman disease? [PDF]

European Journal of Case Reports in Internal Medicine, 2023
Introduction: Multicentric Castleman disease (MCD) is a lymphoproliferative disorder characterized by lymph node histopathology and systemic symptoms.
Gavin Ha, Kelsey Kwong, Bryce Tanaka, Yoshito Nishimura, Christina Chong   +4 more
doaj   +3 more sources